Skip to main content
. 2022 Oct 14;32(10):1184–1192. doi: 10.1089/thy.2022.0115

FIG. 3.

FIG. 3.

(A) Progression-free survival estimates for dabrafenib alone (shown in blue, median [CI] = 10.7 [3.8–34.7] months) and dabrafenib + trametinib (shown in red, 15.1 [12.3–37.3] months). (B) Overall survival estimates for dabrafenib alone (37.9 [23.4–NR] months) and dabrafenib + trametinib (47.5 [27.9–57.8] months). NR, not reached; PFS, progression free survival.